About the author:Dr. Liz Kwo is currently the staff VP of clinical data analytics at Anthem, and previously cofounded and served as CEO of telemedicine second opinion company InfiniteMD. She received anMDfrom Harvard Medical, an MBA from Harvard Business School and an MPH from the Harvard T.H. Chan School of Public Health.

COVID-19 has reshaped the way humans interact with technology in healthcare. Many countries have responded with public health measures such as social distancing, masks, and quarantine for suspected and confirmed cases.Intelligent data, technology, artificial intelligence (AI)and machine learning (ML) havestarted to lighten the burden to establish new ways for both health system supply and demand sustainability.

Among the most visible promoters of digital health arenext-generation payers and providers (NGPPs). These companies, many of them created after implementation of the Affordable Care Act (ACA), have commonly adopted the belief that technology is the solution to improving the healthcare system. Their focus is on delivering technology-enabled solutions to improve clients, such as employers' but more importantly, patients' as the end-user's experiences. These companies are using concepts such as blockchain, telehealth, web applications and genomics.

COVID-19 has prompted more healthcare organizations to embrace the idea of intelligent data as a tool for migration to digital health. Several companies are teaming up with startups that have the means to deliver technology-enhanced solutions either by allowing these startups to connect to their systems or by creating a customer-vendor type of relationship.

Connecting a smaller startup to a healthcare companys mainframe or command center means the startup involved in the process must codevelop solutions customized to the systems processes, flows, infrastructure and objectives. By accessing the companys platforms, whether a payor or provider through an electronic health record (EHR), a customer relationship management(CRM) system or other approach, the startup provides valid solutions based on the current status.

The solutions are not limited to identifying problems and providing fixes, but must extend to presenting innovations that enable the company to improve their patient records, deal more efficiently with aggregated and dispersed data, and handle a larger amount of information collected from various sources.

For example, collecting data run through predictive analytics via biometric devices that are connected remotely enables clinicians to complete their tasks at a higher speed with increased accuracy if the insights are actionable, potentially reducing medical costs if treatment or interventions can be determined correctly that arecustomized to the patient.

However, the downside of this type of cooperation is that it requires mobilization of massive internal resources, a relationship built on mutual trust and the willingness to share the risk among stakeholders such as providers, technology-enablement service companiesand payors. Therefore, health companies look to startup companiesfor innovative solutions that can be easily integrated in their workflows with ready-to-implement solutions, such as technology enabling remote consults between patients and care providers.

AI, for instance, requires multiple levels of mutual agreement between the healthcare companies and collaborative startups for processes such as data sharing privacy and security, liability protections, validation of models, and ongoing monitoring of progress and milestones. The implementation of AI in clinics has specific requirements, such as the availability of a workforce trained to use digital tools, remote access to the latest technologies, and knowledge and willingness from both clinicians and patients to adopt these tools.

AI has produced valuable techniques that are in place and will continue to improve in triaging care via chatbots, models for data integration that enable a better and faster illness prognosis, predicting illness progression through medical records, and detecting anomalies for fraud prevention in claims or to ensure proper claims payments.

Blockchain provides a change of secure and accurate information between nodes (e.g. patients, organizations andclinicians) with the help of a databasethat doesnt require control from a third party. Blockchain enables organizations to conduct trusted transactions and to reduce their administrative costs by sharing a common ledger instead of maintaining their own, separate data.

All the organizations participating in the blockchain have access to the shared data and can instantly protect it if accessed by unauthorized users. In the healthcare sector, blockchain is still in the early stages, and faces challenges such as the network effect, meaning that all parties sharing the blockchain must be willing to work together in testing and evaluating the advantages of this technology, which is easier said than done.

Deploying blockchain for provider access can mean that patients who are not able to find a doctor in their network can have access to a wider pool of physicians, hence benefiting from faster and improved access to care.

Telehealth (also referred to as e-health, mobile-healthor telemedicine) represents a means to remotely access medical services with the help of digital technologies such as laptops, smartphones and any mobile devices.

Among the objectives of telemedicine:

Examples of what telehealth can provide include:

Telehealth was used before COVID-19 in various formsas an instrument to train doctors in treating complex diseases in rural areas via video conference, such as the partnership between Medicaid and Extension for Community Healthcare Outcomes (ECHO) put in place at the University of Mexico,or as remote consultations with the use of symptom checkers defined by user inputs adopted in Spain by Mediktor.

COVID-19 brought a huge increase in Telehealth adoption. In the U.S., telehealth became used by 45% of consumers in COVID-19 era, compared to 11% of consumers in 2019 that called on this method to replace healthcare trips to the doctors office. Before the pandemic, the main players in the U.S. telehealth sector focused their services on urgent care areas by providing patients telehealth visits on demand. If before COVID-19 the estimated yearly revenues of U.S. telehealth companies were $3 billion, its estimated that in the next years up to $250 billion of current U.S. healthcare market could be invested in the virtualization of medical assistance through telehealth.

Telehealth, however, has its own challenges. Providers will need to adopt new ways of working;the exchange of concise and useful information must be improved;wider access and integration of technology is required;and clear data security measures must be in place. The effectiveness of telehealth compared to in-person visits will be closely measured, and reimbursement policies will have to be established and implemented properly.

For patients, the awareness and education of telehealth benefits must be understood, such as specific use cases to transmit valid information, the medical needs that telehealth can address, and understanding the insurance coverage of the service. These challenges can be surmounted, considering telehealth has the potential to bring benefits for patients, decrease costs for payers, increase efficiency for medical staffandimprove overall healthcare experience.

Web applications were developed as a response to the consumers expectations to have instant access to information. The healthcare market is currently dominated by two types of applications: ones that collect and record data regarding the health of clients (that can be shared with care providers and health insurance companies) and applications that provide access to health-related information such as health and wellness programs or provider and medical recommendations.

Mobile applications provided by some health insurance companies offer clients the opportunity to become more engaged in building their own team of healthcare providers, in order to compare prices of various services and to have autonomy in their overall health. With a few clicks, patients can locate providers inside and outside their network, choose an emergency room or urgent care center they need, or find a specialist that is available with a next-day appointment.

Many applications are populated with a huge database that delivers enormous amounts of informationin multiple languageson topics such as diseases, symptomsand medications, and are reviewed by prestigious medical professionals. Other applications are focused on prevention, helping people maintain good health by focusing them on behaviors such as motivational exercise or mindful eating, as in controlling consumption by documenting the foods they intend to eat and the impact on their health. They can calculate the caloric intake and compare foods to make better decisions.

Aside from the benefits brought to patients, web applications help providers collaborate with their patients. Applications that measure and monitor patient heart rates and blood sugar levels are equipped with triggers that send alerts when indicators reach a certain level. The alert is sent to the doctors that monitor those clients. Based on the reading and the medical history,the doctors can suggest a next step. As more people adopt these web applications, the tools will only become easier and faster to use as they improve over time.

The human genome, considered the blueprint of the human body, holds the potential biological plan for each individual. The link between a typical genome versus variants that may lead to disease can be established by analyzing a huge amount of medical records and genetic data. This is a complex, time-consumingmatching process.

The combined use of AI, machine learningand genomics brings to healthcare what has been missing in this discovery process: simplification and more accurate results in a lot shorter period of time. This can be achieved by integrating, for example, genomics with lab results, EHRs that include pathology, and imaging. T

This integration provides a more comprehensive look into a patient, which translates into better decisions taken by a supervising doctor andthe improved ability to forecast disease and to provide customized treatment and medication based on prediction patterns and the efficacy of a medication for the individual. By improving the ability to predict and treat, the costs of healthcare can be reduced by eliminating unnecessary lab tests or ineffective treatments.

The challenge in utilizing genomic data is translating this knowledge to real-world use cases. Pharmacogenomics is the use of genetic testing to inform medication-management decisions, which can improve patient outcomes and reduce health cost. For example, genomic data is used to determine treatment options for cancer patients.

This type of precision medicine creates a new consumer healthcare market for people to determine the influencing factors of their health, with extraordinary levels of treatment personalization across various chronic conditions. As patients ask their providers for advice and payers for coverage in this growing market, providers will need clear training to understand the right tests to order, how to interpret the results, and how to properly inform their patients about the results.

The costs of these tests have significantly decreased over time, but an adequate understanding of the benefits is required to achieve actionable insights from the results.

The progress made in intelligent data and AI use in the healthcare sector is surging. It is vital to ensure that all patients have access and affordable healthcare utilizing efficient tools and customized treatments that rely on intelligent data for groundbreaking innovations in healthcare.

View post:
How intelligent data transforms health in the time of COVID-19 - Mobihealth News

Recommendation and review posted by Bethany Smith

Point-of-Care Genetic Testing Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026)

A comprehensive research study on the Point-of-Care Genetic Testing Market was recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario. The changes in the market conditions are drastic. The swiftly changing market scenario and initial and future assessment of the impact on Point-of-Care Genetic Testing market is covered in the report.

An Outline of the Major Key Players covered in this Report:Abbott (US), Roche (Switzerland), Thermo Fisher Scientific (US), Cepheid (US), IQuum (US), Biocartis (Switzerland), Idaho Technologies (US), Optigene (UK), Lumora (UK)

Request a Sample Report of Point-of-Care Genetic Testing Market @ https://www.marketreportexpert.com/report/Point-of-Care Genetic Testing/2451/sample

The report puts together a succinct analysis of the growth drivers influencing the current business scenario across various regions and countries. Substantial information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present a collaborative prediction. Additionally, this report encompasses a precise competitive analysis of major market players, innovative companies, and their strategies during the projection timeline.

The latest report on the Point-of-Care Genetic Testing Market consists of an analysis of this industry and its type, application, and other segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period of 2020-2026.

Majortype, primarily split intoPOCT Cancer Kits, Molecular POC Kits, POCT In Antibiotic Therapies, Assay Cartridge, Other.

Major applications/end users, includingDiagnostic Labs, Bio-Pharmaceutical Industry, Academic Institutions, Other.

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

The research offers an analysis of the geographical landscape of the Point-of-Care Genetic Testing Market, which is divided into regions such as North America, Europe, Asia Pacific, South America, and the Middle East & Africa.The segment includes data about several parameters related to the regional contribution such as market share, application share, type share, key companies in respective regions, market share of key companies in regional market, growth rate and revenue of the regional market, sales, production, and consumption of the respective Point-of-Care Genetic Testing market.

Major Table of Content Covers:

1 Study Coverage1.1 Point-of-Care Genetic Testing Market Product Introduction1.2 Point-of-Care Genetic Testing Market Segments1.3 Point-of-Care Genetic Testing Market Manufacturers Covered: Ranking by Revenue1.4 Point-of-Care Genetic Testing Market by Type1.4.1 Global Point-of-Care Genetic Testing Market Market Size Growth Rate by Type1.5 Point-of-Care Genetic Testing Market by Application1.5.1 Global Point-of-Care Genetic Testing Market Market Size Growth Rate by Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Point-of-Care Genetic Testing Market Market Size, Estimates and Forecasts2.1.1 Global Point-of-Care Genetic Testing Market Revenue 2015-20262.1.2 Global Point-of-Care Genetic Testing Market Sales 2015-20262.2 Global Point-of-Care Genetic Testing Market, Market Size by Producing Regions: 2015 VS 2020 VS 20262.2.1 Global Point-of-Care Genetic Testing Market Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Point-of-Care Genetic Testing Market Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Point-of-Care Genetic Testing Market Competitor Landscape by Players3.1 Point-of-Care Genetic Testing Market Sales by Manufacturers3.1.1 Point-of-Care Genetic Testing Market Sales by Manufacturers (2015-2020)3.1.2 Point-of-Care Genetic Testing Market Sales Market Share by Manufacturers (2015-2020)3.2 Point-of-Care Genetic Testing Market Revenue by Manufacturers3.2.1 Point-of-Care Genetic Testing Market Revenue by Manufacturers (2015-2020)3.2.2 Point-of-Care Genetic Testing Market Revenue Share by Manufacturers (2015-2020)3.2.3 Global Point-of-Care Genetic Testing Market Market Concentration Ratio (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Point-of-Care Genetic Testing Market Revenue in 20193.2.5 Global Point-of-Care Genetic Testing Market Market Share by Company3.3 Point-of-Care Genetic Testing Market Price by Manufacturers3.4 Point-of-Care Genetic Testing Market Manufacturing Base Distribution, Product Types3.4.1 Point-of-Care Genetic Testing Market Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Point-of-Care Genetic Testing Market Product Type3.4.3 Date of International Manufacturers Enter into Point-of-Care Genetic Testing Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)4.1 Global Point-of-Care Genetic Testing Market Size by Type (2015-2020)4.1.1 Global Point-of-Care Genetic Testing Market Sales by Type (2015-2020)4.1.2 Global Point-of-Care Genetic Testing Market Revenue by Type (2015-2020)4.1.3 Point-of-Care Genetic Testing Market Average Selling Price (ASP) by Type (2015-2026)4.2 Global Point-of-Care Genetic Testing Market Size Forecast by Type (2021-2026)4.2.1 Global Point-of-Care Genetic Testing Market Sales Forecast by Type (2021-2026)4.2.2 Global Point-of-Care Genetic Testing Market Revenue Forecast by Type (2021-2026)4.2.3 Point-of-Care Genetic Testing Market Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Point-of-Care Genetic Testing Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)5.1 Global Point-of-Care Genetic Testing Market Size by Application (2015-2020)5.1.1 Global Point-of-Care Genetic Testing Market Sales by Application (2015-2020)5.1.2 Global Point-of-Care Genetic Testing Market Revenue by Application (2015-2020)5.1.3 Point-of-Care Genetic Testing Market Price by Application (2015-2020)5.2 Point-of-Care Genetic Testing Market Size Forecast by Application (2021-2026)5.2.1 Global Point-of-Care Genetic Testing Market Sales Forecast by Application (2021-2026)5.2.2 Global Point-of-Care Genetic Testing Market Revenue Forecast by Application (2021-2026)5.2.3 Global Point-of-Care Genetic Testing Market Price Forecast by Application (2021-2026)

6 North America6.1 North America Point-of-Care Genetic Testing Market by Country6.1.1 North America Point-of-Care Genetic Testing Market Sales by Country6.1.2 North America Point-of-Care Genetic Testing Market Revenue by Country6.1.3 U.S.6.1.4 Canada6.1.5 Mexico6.2 North America Point-of-Care Genetic Testing Market Facts & Figures by Type6.3 North America Point-of-Care Genetic Testing Market Facts & Figures by Application

7 Europe7.1 Europe Point-of-Care Genetic Testing Market by Country7.1.1 Europe Point-of-Care Genetic Testing Market Sales by Country7.1.2 Europe Point-of-Care Genetic Testing Market Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Point-of-Care Genetic Testing Market Facts & Figures by Type7.3 Europe Point-of-Care Genetic Testing Market Facts & Figures by Application

8 Asia Pacific8.1 Asia Pacific Point-of-Care Genetic Testing Market by Region8.1.1 Asia Pacific Point-of-Care Genetic Testing Market Sales by Region8.1.2 Asia Pacific Point-of-Care Genetic Testing Market Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Point-of-Care Genetic Testing Market Facts & Figures by Type8.3 Asia Pacific Point-of-Care Genetic Testing Market Facts & Figures by Application

9 Latin America9.1 Latin America Point-of-Care Genetic Testing Market by Country9.1.1 Latin America Point-of-Care Genetic Testing Market Sales by Country9.1.2 Latin America Point-of-Care Genetic Testing Market Revenue by Country9.1.3 Brazil9.1.4 Argentina9.2 Central & South America Point-of-Care Genetic Testing Market Facts & Figures by Type9.3 Central & South America Point-of-Care Genetic Testing Market Facts & Figures by Application

10 Middle East and Africa10.1 Middle East and Africa Point-of-Care Genetic Testing Market by Country10.1.1 Middle East and Africa Point-of-Care Genetic Testing Market Sales by Country10.1.2 Middle East and Africa Point-of-Care Genetic Testing Market Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Point-of-Care Genetic Testing Market Facts & Figures by Type10.3 Middle East and Africa Point-of-Care Genetic Testing Market Facts & Figures by Application

11 Company Profiles11.1.1 Company Corporation Information11.1.2 Company Description and Business Overview11.1.3 Company Sales, Revenue and Gross Margin (2015-2020)11.1.4 Company Point-of-Care Genetic Testing Market Products Offered11.1.5 Company Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)12.1 Point-of-Care Genetic Testing Market Estimates and Projections by Region12.1.1 Global Point-of-Care Genetic Testing Market Sales Forecast by Regions 2021-202612.1.2 Global Point-of-Care Genetic Testing Market Revenue Forecast by Regions 2021-202612.2 North America Point-of-Care Genetic Testing Market Size Forecast (2021-2026)12.2.1 North America: Point-of-Care Genetic Testing Market Sales Forecast (2021-2026)12.2.2 North America: Point-of-Care Genetic Testing Market Revenue Forecast (2021-2026)12.2.3 North America: Point-of-Care Genetic Testing Market Size Forecast by Country (2021-2026)12.3 Europe Point-of-Care Genetic Testing Market Size Forecast (2021-2026)12.3.1 Europe: Point-of-Care Genetic Testing Market Sales Forecast (2021-2026)12.3.2 Europe: Point-of-Care Genetic Testing Market Revenue Forecast (2021-2026)12.3.3 Europe: Point-of-Care Genetic Testing Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Point-of-Care Genetic Testing Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Point-of-Care Genetic Testing Market Sales Forecast (2021-2026)12.4.2 Asia Pacific: Point-of-Care Genetic Testing Market Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Point-of-Care Genetic Testing Market Size Forecast by Region (2021-2026)12.5 Latin America Point-of-Care Genetic Testing Market Size Forecast (2021-2026)12.5.1 Latin America: Point-of-Care Genetic Testing Market Sales Forecast (2021-2026)12.5.2 Latin America: Point-of-Care Genetic Testing Market Revenue Forecast (2021-2026)12.5.3 Latin America: Point-of-Care Genetic Testing Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Point-of-Care Genetic Testing Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Point-of-Care Genetic Testing Market Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Point-of-Care Genetic Testing Market Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Point-of-Care Genetic Testing Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Point-of-Care Genetic Testing Market Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Point-of-Care Genetic Testing Market Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer

Inquiry Before Buying to purchase this [emailprotected] https://www.marketreportexpert.com/report/Point-of-Care Genetic Testing/2451/inquiry

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email [emailprotected]9th Street, 2nd Floor, Kansas City, Missouri, 64105, United States of America.

Excerpt from:
Global Point-of-Care Genetic Testing Market: Things to Focus on to Ensure Long-term Success| Abbott (US), Roche (Switzerland), Thermo Fisher...

Recommendation and review posted by Bethany Smith

COVID-19 Analysis on the Global Preimplantation Genetic Testing Market

A recent market research report on the Preimplantation Genetic Testing market published by Fact.MR is an in-depth assessment of the current landscape of the market. Further, the report elaborates on the impact of the COVID-19 on the Preimplantation Genetic Testing market and provides a thorough understanding of the growth potential of each market segment over the forecast period (2020-2030).

According to the analyst at Fact.MR, the Preimplantation Genetic Testing market is evenly slated to register a CAGR growth of ~XX% during the assessment period and attain a value of ~US$ XX by the end of 2030. The report analyzes the micro and macro-economic factors that are projected to impact the growth of the Preimplantation Genetic Testing market in the upcoming years. Further, a detailed analysis of the business continuity strategies of leading market participants is enclosed in the presented report.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=292

Key Insights Enclosed in the Report

Segmentation of the Preimplantation Genetic Testing Market

The presented report dissects the Preimplantation Genetic Testing market into different segments and ponders over the current and future prospects of each segment. The report depicts the year-on-year growth of each segment and touches upon the different factors that are likely to influence the growth of each market segment. Further, projections are made taking into account the impact of the COVID-19 pandemic on the each market segment.

The various segments of the Preimplantation Genetic Testing market analyzed in the report include:

Competition Tracking

The report also profiles companies operating in the preimplantation genetic testing market, which include Agilent Technologies Inc., Abbott Laboratories, CooperSurgical Inc., Oxford Gene Technology IP, Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Genea Limited, Natera, Inc., Rubicon Genomics, Inc., and CombiMatrix Corporation.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=292

Important doubts related to the Preimplantation Genetic Testing market clarified in the report:

Why Choose Fact.MR

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=292

Read the rest here:
Preimplantation Genetic Testing Market with Current Trends Analysis 2017 to 2022 - StartupNG

Recommendation and review posted by Bethany Smith

We know that dogs can be diagnosed with brain tumours however this is the first time we have reported on positive results in a preliminary brain cancer study for the treatment of dogs. Animal Life Sciences, Inc. (ALS), a pharmaceutical and nutritional development company announced that a comparative oncology trial being conducted using ALS101( a combination of two brain cancer drug candidates ALS licensed for use in animals) is showing promise in dogs suffering from malignant gliomas, including glioblastoma. Dogs suffer from these same types of aggressive tumours and treatment options, much like those for humans, are extremely limited. ALS have seen regression of tumour in a significant population of dogs treated in a formal Phase I clinical trial and while the tumour did not quite disappear, in some cases it shrank more than 95 percent and the animals lived longer.

News from Sweden now where a study has shown that one year after the diagnosis of low-grade malignant brain tumour just under three people in ten were in full-time employment. For this young patient group, returning to work is a key health factor however another year later, the proportion remained below half. For those of you unsure about the characterisation of a low grade, malignant tumour it is defined in this study as a low-grade glioma which is incurable and grows slowly but, thanks to modern treatments, its survival expectancy has successively increased. Given the patients' low age -- averaging 40 years when they fell ill -- their work capacity is seen as an especially important factor in quality of life. Being able to work again is, for many, a crucial aspect of returning to a normal life.

We have explained about orphan drug diagnosis in these updates before but to recap, in the US the Orphan Drug Act (ODA) provides for granting special status to a drug to treat a rare disease or condition. Benefits for a pharma company of having a drug given orphan designation include tax credits of 50% off the clinical drug testing cost awarded upon approval and eligibility for market exclusivity for 7 years post-approval.

Plus Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for its lead investigational drug, Rhenium NanoLiposomes (RNL) for the treatment of patients with recurrent glioblastoma. RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation - up to 25 times greater concentration than currently used external beam radiation therapy - directly into the brain tumour for maximum effect. Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics said: We believe RNL has the potential to prolong survival for patients with malignant brain tumours and that of other difficult to treat radiosensitive tumours.

In the fight against cancer, scientists have long grappled with the ambiguous nature of stem cells. GBM tumours consist of stem cells which have the ability to self-renew making these tumours notoriously hard to treat with targeted radiation therapy and difficult to permanently remove through surgery. However, could gene therapy provide a potential breakthrough in brain cancer treatment and put the invincibility of tumour stem cells into question. This recent paper details a new technique of sensitizing stem cells to radiation therapy, thereby increasing the therapys efficacy.

You may find this overview of dendritic cell vaccines for brain tumours is helpful reading before moving onto this paperOnce, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. John Sampson, M.D., Ph.D. from Duke University a leader in cancer immunotherapy for brain tumours commented on the paper saying These study results not only advance our understanding of a virus role in cancer, but they also signal tremendous hope to patients and their families suffering from this devastating disease

An optimistic-sounding end to this weeks worldwide research update.

Related reading:

If you found this story interesting or helpful, sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

Originally posted here:
Treating dogs diagnosed with GBM, getting Swedish patients back to work, orphan designation for improved radiotherapy drug plus gene therapy - Brain...

Recommendation and review posted by Bethany Smith

Sarepta has gone all-in on gene therapy over the last few years, racing with Pfizer and Solid Biosciences to be the first to develop a genetic fix for Duchenne muscular dystrophy, one of the most common rare diseases.

Sarepta has been comfortably in the lead, collecting the first positiveresults and snaring a $1.15 billion cash commercialization deal with Roche, but this week the company hit a snag. Late yesterday, Sarepta provided a program update for its gene therapy, revealing that in a scheduled meeting the FDA had raised concerns about the kinds of tests they would use to measure potency in the pivotal study and commercial supply for the gene therapy. The company has assays that might fit the criteria, they said, but needed additional dialogue with the agency to confirm.

Unlock this story instantly and join 89,800+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read more here:
FDA knocks back Sarepta in Duchenne gene therapy race with Pfizer, but analysts urge caution - Endpoints News

Recommendation and review posted by Bethany Smith

RESEARCH TRIANGLE PARK Dont call it AveXis anymore. Its now Novartis Gene Therapies.

Novartis has announced the renaming of its previously acquired AveXis gene therapy arm because of the growing importance of gene therapy to building a leading, focused medicines company with advanced therapy platforms.

AveXis, headquartered in Bannockburn, Illinois, was purchased in 2018 for $8.7 billion by the Swiss drugmakerNovartis.

The company announced early last year that it would put $60 million more into its then-new $55 million Durham County manufacturing facility, doubling the workforce here from 200 to 400. Now, according to a Novartis spokesperson, there are more than 400 people working at the Durham site, and more are being hired while the site is anticipating final FDA operational approval in 2021.

The company makes gene therapies for neurological genetic diseases. Its initial product is Zolgensma (onasemnogene abeparvovec-xioi), a gene replacement therapy to treat spinal muscular atrophy (SMA) Type 1, a deadly neuromuscular disease with limited treatment options.

AveXispurchased rightsto its gene therapy technology in 2015 for an undisclosed sum fromAsklepios BioPharmaceutical, a Chapel Hill gene therapy platform company commonly called AskBio.

AskBio said it received an upfront payment and stands to gain milestone payments and royalties based on AveXis successful development and commercialization of its treatment.

AskBios gene therapy platform is based on the work of Jude Samulski, Ph.D., a pioneering scientist in gene therapy who was recruited to the University of North Carolina School of Medicine from the University of Pittsburgh in 1993 with the help of about $250,000 in grant funding from the North Carolina Biotechnology Center. Samulski, renowned for his development of the harmless adeno-associated virus (AAV) as a vector, or delivery tool, for genes, directed UNCs Gene Therapy Center for many years.

Building on the success of Zolgensma, Novartis Gene Therapies said it will be responsible for the research, development, manufacturing and commercialization of the next wave of AAV-based innovative gene therapies. Novartis Gene Therapies will also provide manufacturing support for gene therapy work conducted by other Novartis units.

DavidLennon, Ph.D., previously president of AveXis, is now president of Novartis Gene Therapies and will continue reporting to Vas Narasimhan, CEO of Novartis.

Novartis sees tremendous potential in the future of gene therapy, and weve seen the impact gene therapy can have on so many lives, said Narasimhan. With the creation of Novartis Gene Therapies, we will continue to advance our gene therapy pipeline for rare genetic diseases, to accelerate the delivery of transformative innovation in areas of high unmet need, and to reimagine medicine for patients all around the world.

The most widely used gene therapy in the world, Zolgensma treats SMA, the leading genetic cause of infant death. If left untreated in its most common form, SMA leads to death or the need for permanent ventilation by the age of 2 in more than 90% of cases.

To date, more than 600 patients have been treated with Zolgensma, including in clinical trials, commercially and through managed access programs. In addition to Zolgensma being approved in the U.S., its approved in Japan, Europe and Brazil.

Novartis Gene Therapies is pursuing Zolgensma registration in close to three dozen countries with regulatory decisions anticipated in Switzerland, Canada, Australia, Argentina and South Korea in late 2020 or early 2021.

Novartis said the change to Novartis Gene Therapies is the natural evolution as the company scales up to deliver Zolgensma globally and expand its reach via a robust pipeline of AAV-based gene therapies for rare genetic diseases including investigational treatments for Rett syndrome, a genetic form of amyotrophic lateral sclerosis (ALS) and Friedreichs ataxia.

Novartis Gene Therapies also establishes a seamless global presence for Zolgensma and the gene therapies to come. Instead of alternating between the AveXis and Novartis umbrella brands by market, the company comes together under one banner as a unified entity.

Our patients and their families are the motivation for everything that we do, and under the banner of Novartis Gene Therapies, our dedicated team will continue to create a lifetime of possibilities to people suffering from rare genetic diseases, said Lennon.

Becoming Novartis Gene Therapies symbolizes the importance of our gene therapy advances for the future of Novartis and our industry leadership at large.

Novartis Gene Therapies comprises more than 2,000 employees across corporate, manufacturing and research facilities in the U.S. (Illinois, North Carolina, Colorado, California); Zurich, Switzerland; and Tokyo. With nearly 1 million square feet of gene therapy manufacturing capacity, Novartis Gene Therapies is the worlds largest gene therapy manufacturer.

(C) N.C. Biotech Center

Read the original:
Novartis Gene Therapies is new name for gene therapy firm with growing RTP presence - WRAL Tech Wire

Recommendation and review posted by Bethany Smith

In nearly 40 years of the HIV epidemic, only two people have likely been cured of the virus. Both scenarios resulted from stem cell transplants needed to fight blood cancers such as leukemia. Inspired by these two cases, a team of scientists is studying a multipronged way to potentially control HIV without medication. It involves two different genetic alterations of immune cells and with a safer method of stem cell transplants, also referred to as bone marrow transplants, a procedure that is generally toxic and dangerous.

The research is being funded by a five-year $14.6 million grant from the National Institutes of Health. The scientists coleading the preclinical studies are Paula Cannon, PhD, a distinguished professor of molecular microbiology and immunology at the Keck School of Medicine of the University of Southern California, and Hans-Peter Kiem, MD, PhD, who directs the stem cell and gene therapy program at the Fred Hutchinson Cancer Research Center, also known as Fred Hutch. According to a Keck School of Medicine press release, the two other main partners are David Scadden, MD, a bone marrow transplant specialist and professor at Harvard University and the Harvard Stem Cell Institute, and the biotechnology company Magenta Therapeutics.

In the HIV cure scenariosinvolving the so-called Berlin and London patientsboth men received stem cell transplants from donors with a natural genetic mutation that made them resistant to HIV. Specifically, their genes resulted in immune cells that lack CCR5 receptors on their surface (HIV latches onto these receptors to infect cells). Unfortunately, this method isnt viable for the nearly 38 million people worldwide living with HIV. Not only is it expensive, toxic and riskyit involves wiping out the patients immune system and replacing it with the new immune cellsbut it also requires matched donors who are CCR5 negative. According to the press release, about 1% of the population have this mutation.

With funding from this new grant, researchers hope to overcome these challenges in several ways. First, Cannon has already developed a gene-editing method to remove the CCR5 receptors from a patients own stem cells. She now hopes to further genetically engineer stem cells so they release antibodies that block HIV.

Our engineered cells will be good neighbors, Cannon said in the press release. They secrete these protective molecules so that other cells, even if they arent engineered to be CCR5 negative, have some chance of being protected.

Fred Hutchs Kiem will use CAR-T therapya new method of genetically modifying immune cells that is emerging out of cancer researchwith the goal of creating T cells that attack HIV-infected cells.

In addition, other scientists involved in the federal grant aim to develop less toxic methods of bone marrow transplantationfor example, by reducing the amount of chemotherapy required and speeding up the process of creating the new immune system.

The research finding could translate to other illnesses, such as cancer, sickle cell anemia and autoimmune disorders.

A home run would be that we completely cure people of HIV, Cannon said. What Id be fine with is the idea that somebody no longer needs to take anti-HIV drugs every day because their immune system is keeping the virus under control so that it no longer causes health problems and, importantly, they cant transmit it to anybody else.

For the latest on the cure cases, see Famed London Man Probably Cured of HIV from earlier this year. And in related news, see $14M Federal Grant to Research CAR-T Gene Therapy to Cure HIV.

See the original post:
$14.6M Grant to Explore a Therapy to Control HIV Without Meds - POZ

Recommendation and review posted by Bethany Smith

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan, an accomplished biotechnology executive, to the Company's Board of Directors.

"We are pleased to welcome Kenneth to the Sangamo Board of Directors," said Sandy Macrae, Chief Executive Officer of Sangamo. "We believe that Kenneths 25 years of clinical development and executive leadership experience, as well as his current focus on the therapeutic applications of DNA sequencing data, will provide great benefit to Sangamo as we continue to advance our growing pipeline of genomic medicines through clinical development.

Since 2019, Dr. Hillan has served as Head of Therapeutics of 23andMe, the consumer genetics and research company, leading a dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases. Previously, Dr. Hillan held leadership roles in the biotechnology industry. He served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of Immunology, Tissue Growth and Repair; Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentechs Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. From 2011 to 2017, he was Chief Executive Officer of Achaogen, Inc., where he was also a member of the Board of Directors. He has also served on the Board of Directors of Zymeworks since February 2017, and was a member of the Board of Directors of Relypsa from 2014 until 2016, when it was acquired by Galenica AG.

Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. He is a Fellow of the Royal College of Surgeons (FRCS, Glasg), and a Fellow of the Royal College of Pathologists (FRCPath). Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.

Sangamo also today announced that Stephen Dilly, M.B.B.S., Ph.D. will resign from the Board of Directors effective September 30, 2020.

It has been a great pleasure serving as a Sangamo director for the past decade, said Dr. Dilly. With a broad therapeutic pipeline, meaningful collaborations with global biopharmaceutical companies, and a strong balance sheet, Sangamo is well positioned as a leader in the field of genomic medicine. I'm personally very pleased to welcome Kenneth Hillan to the Board and am excited for the future success of Sangamo."

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit http://www.sangamo.com.

Forward Looking Statements

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize therapies to treat genetic diseases and the timing thereof, the anticipated benefits of Sangamos collaborations, Sangamos financial resources and expectations and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the operations and business environments of Sangamo and its collaborators. These risks and uncertainties are described more fully in Sangamo's Securities and Exchange Commission filings and reports, including in Sangamos Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

See the rest here:
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors - Business Wire

Recommendation and review posted by Bethany Smith

After immune modulators and antibodies, blood thinners are the next class of drugs to be put through a Phase III trial organized under the NIHs ACTIV initiative.

Three different anticoagulants have been named for the master protocol: heparin, aspirin and apixaban. Informed by studies suggesting that many patients who died from Covid-19 have formed unusual blood clots throughout their bodies including in their smallest blood vessels the NIH wants to see which therapies are the most effective at preventing or reducing them and thus improving outcomes for patients.

There is currently no standard of care for anticoagulation in hospitalized COVID-19 patients, and there is a desperate need for clinical evidence to guide practice, agency head Francis Collins said in a statement. Conducting trials using multiple existing networks of research sites provides the scale and speed that will get us answers faster.

For the inpatient trial, patients will be given either a low dose or a high dose of heparin.

But hospitalized patients are just one of two groups now being recruited to ACTIV-4, which also includes an outpatient trial broken down into four cohorts given placebo, aspirin, or a low or therapeutic dose of the blood thinner apixaban. The goal there is to reduce life-threatening cardiovascular or pulmonary complications in newly-diagnosed Covid-19 patients who dont need hospital admission.

Gary Gibbons, director of the National Heart, Lung, and Blood Institute, said while heparin has shown promise, physicians really need clinical trial data to determine how much blood thinner, or even anti-platelet medication, to give.

A third trial will start soon involving patients who had moderate or severe disease but have been discharged after hospitalization. It has a slightly different design, with the key metric being whether patients develop thrombotic complications (think heart attack, stroke, blood clots in major veins or arteries and death) within 45 days of being hospitalized.

As is custom in these master protocols, researchers may switch out candidates or add in new therapies as clinical data emerge.

NHLBI is coordinating and overseeing the program, while Operation Warp Speed is providing the funding. Amber Tong

The JP Morgan Healthcare Conference just got a whole lot cheaper.

On Thursday, the bank told clients that the famed conference was going virtual. That means no more packing into ballrooms and conference halls, no more dashing between different hotel rooms for an endless circle of meetings, and crucially no more $2,000 suites and $150 rent-a-tables. Instead, there will only be what there has been for the last 6 months: Endless circles of Zoom meetings, looped in infinite recursion from San Diego to Boston to Cambridge, UK.

The virtual conference means that, after years of chatter, the conference will finally, at least for a year, leave San Francisco. In theory, though, you could still go. A room at the Westin is selling for only $276, breakfast not included. Jason Mast

Longtime FDA officials and drug companies are trying to shore up public confidence in an eventual Covid-19 vaccine, but a new poll suggests that, at least until the election, they could be facing an uphill battle.

The poll, conducted by theKaiser FamilyFoundation,found that most adults, both Republican and Democrat, are wary of taking a vaccine before the election. Six in ten adults, meanwhile, were worried that the Trump Administration would pressure the FDA to rush an approval. The poll was conducted between August 28 and September 3 days after a heavily politicized emergency use authorization for convalescent plasma stoked fears that a vaccine would be authorized under similar conditions.

Fear of political pressure was most acute among Democrats, 51% of whom said they were very worried and 85% of whom were at least somewhat worried. A majority of Republicans said they were not too worried or not at all worried, although 35% expressed some concern.

As to whether they would take a vaccine, though, the splits are reversed. Half of Democrats were willing to take a vaccine, but only 36% of Republicans said they would. These numbers are in linewith long-running differences between Democrats and Republicans on vaccination, though it does suggest that recent events may have dented views. A Gallup pollconducted in late July and early August found 81% of Democrats and 47% of Republicans were willing to take an an FDA-approved vaccine to prevent coronavirus/COVID-19 if it was available right now at no cost. Those questions, though, did not directly reference the election.

Still, most respondents did not think such an eventuality was likely. Eighty-one percent of people, regardless of party, did not expect a vaccine to come before November 3.

The polls come as officials in the US struggle to shore up confidence in any eventually approved vaccine. Earlier this week, 9 major drug companies signed a pledge to only submit vaccine data when it meets safety and efficacy standards and 8 FDA career officialspublishedan open letter in USA Today on their commitment to science. Even before the latest concerns of political interference, public health experts have talked for months about how rising rates of vaccine hesitancy could pose a barrier in pandemic response. Bill Gates has called getting people to actually take a vaccine the final hurdle.

New data highlight how criticalmessaging can be on vaccine uptake. A large study published this morning inThe Lancettracked global vaccine hesitancy from 2015 to 2019 identified misinformation as one of the key factors in places with growing skepticism of vaccines, including South Korea, Malaysia, and Georgia. Anthropologist and director of the Vaccine Confidence Project Heidi Larson, the studys author, said messaging in the US and elsewhere that focused on speed wasnt helping.

Theres a lot of anxiety about the speed of vaccine development (for COVID-19), she told Reuters. But the public is not really keen on speed theyre more keen on thoroughness, effectiveness and safety. Jason Mast

For a look at allEndpoints Newscoronavirus stories, check out ourspecial news channel.

See original here:
Covid-19 roundup: NIH spotlights blood thinners in its next big trial; All it took was a pandemic to get JPM out of SF - Endpoints News

Recommendation and review posted by Bethany Smith

Xtalks Life Science Webinars

TORONTO (PRWEB) September 11, 2020

During the last five years, the number of cell and gene therapies (CGT) have exponentially increased, stimulated by their efficacy and potential for cure. However, CGT can expose the patients to significant toxicities such as cytokine release syndrome (CRS) and neurotoxicities (ICANS), requiring specialised and accurate management associated with precise data capture and analysis. Timely and unrestricted support is crucial for the safe progress of CGT. In addition, dealing with these living therapies represents whats been called the most complex supply chain in the history of medicine.

This webinar will present and discuss the challenges involved in supporting CGT-related clinical trials. Attendees will gain first-hand learning from members of a multidisciplinary team that was developed at ICON for the successful support of CGT clinical trials.The participants will learn the following during the presentation:

A The medical landscape:

B Operational management:

C Commercialisation and logistics

Join Anne S. Renteria, MD, Medical Director, Medical Affairs, ICON plc, Brandon Fletcher, PhD, Principal, Clinical Project Management, ICON plc and Tamie Joeckel, Business Lead, Cell and Gene Therapy Center of Excellence, ICON plc in a live webinar on Thursday, September 24, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit Achieving Quality Cell and Gene Therapies Outcomes Through Multidisciplinary Collaboration.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Follow this link:
Achieving Quality Cell and Gene Therapies Outcomes Through Multidisciplinary Collaboration, Upcoming Webinar Hosted by Xtalks - PR Web

Recommendation and review posted by Bethany Smith

Boehringer Ingelheim wants in on digital therapeutics.

The German pharma signed an up to $500 million collaboration with Click Therapeutics, one of a handful of major companies developing prescription computer and smartphone applications for various neurological or mental disorders. They join a small list of pharmas that have decided to test the waters in the emerging field.

Under the deal, Boehringer and Click will co-develop a digital therapeutic for schizophrenia, known as CT-155. Its a complementary effort to Boehringers more traditional schizophrenia work. The company has concentrated their neuroscience efforts there since 2018, when a Phase II failure blew up their late-stage Alzheimers efforts.

CT-155 is an excellent addition to our CNS pipeline portfolio; it reflects our patient centric approach and translates evidence showing how behavioral modification can induce positive neuronal changes into a widely accessible solution,Cornelia Dorner-Ciossek, Boehringers head of CNS disease research, said in a statement.

Boehringer is at least the third Big Pharma to dip their toes into digital therapeutics. Sanofi Ventures the French giants investment arm led a $17 million funding round for Click in 2018, the same year Mercks venture arm contributed to the video game therapeutics company Akilis $55 million Series C. Novartis also signed a partnership that year with Pear Therapeutics to commercialize Pears FDA-authorized app for substance abuse, although they pulled out of the partnership just one year later.

Boehringers new deal marks one of the first major development partnerships between a large pharma company and a digital therapeutic.

Click has already developed a commercial app for smoking cessation called Clickotine. Clickotine, like the other apps Click has in development for insomnia, migraine and major depressive disorder, among others, uses a variety of smartphone-based features to try to adjust peoples behavior. In Clickotines case, that involves personalized curriculums that offer users live coaching, guided breathing, and personal analytics. That app, though, while backed by a non-controlled study, did not have to be FDA-approved as other apps will.

Click has released little about CT-155 its description on their website reads simply confidential but in theory it could be used alongside existing schizophrenia drugs and, eventually, alongside the schizophrenia meds Boehringer now has in its pipeline. Two such compounds are now in Phase II.

Read the original post:
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone apps - Endpoints News

Recommendation and review posted by Bethany Smith

While there is no cure for blindness and macular degeneration, scientists have accelerated the process to find a cure by visualizing the inner workings of the eye and its diseases at the cellular level.

In an effort led by UW Medicine, researchers successfully modified the standard process of optical coherence tomography (OCT) to detect minute changes in response to light in individual photoreceptors in the living eye.

The results were published Sept. 9 in Science Advances.

"We have now accelerated the life cycle of vision restoration," said lead author Vimal Prabhu Pandiyan, a ophthalmology researcher at the University of Washington School of Medicine.

The study was funded in part by the National Eye Institute's Audacious Goals Initiative, which embraces bold ideas in helping people to see better.

The OCT modifications outlined in the study will help researchers who want to test therapies such as stem cells or gene therapy to treat retinal disease. They now have the tools to zoom in on the retina to evaluate whether the therapy is working.

Corresponding author Ramkumar Sabesan, a UW assistant research professor of ophthalmology, said the only way to objectively measure the eye currently is to look at a wide retinal area. Sabesan said researchers currently can attach electrodes on the cornea but it captures a large area with around 1 million cells. Now they are talking about nanometers, or one billionth of a meter - a small fraction of the size of a cell, providing orders of magnitude improvement.

"Since photoreceptors are the primary cells affected in retinal generation and the target cells of many treatments, noninvasive visualization of their physiology at high resolution is invaluable," the researchers wrote.

Cone photoreceptors are the building blocks of sight, capturing light and funneling information to the other retinal neurons. They are a key ingredient in how we process images and patterns of light falling on the retina.

Optical coherence tomography has been around since the 1990s. In this study, researchers used OCT with adaptive optics, line-scanning and phase-resolved acquisition to deliver the concept of Thomas Young's interference to the human eye. With the ability to zoom in on the retina at high speeds, they found that cone photoreceptors deform at the scale of nanometers when they first capture light and begin the process of seeing.

As Sabesan explained: "You can imagine a picture that looks visually and structurally normal. But when we interrogate the inner working of the retina at a cellular scale, we may detect a dysfunction sooner than what other modalities can do. A doctor then can prescribe medication to intervene early or follow the time-course of its repair via gene therapy or stem cell therapy in the future."

"We will now have a way to see if these therapies are acting in the way they should," Sabesan said.

Read more:
Seeing the eye like never before - Science Codex

Recommendation and review posted by Bethany Smith

By Bruce DePuytSeptember 10, 2020

A 2016 decision to link the research labs at the University of Maryland College Park with those at the University of Maryland at Baltimore is paying dividends in the competition for federal COVID-19 research dollars, a top education official told a science advisory panel on Wednesday.

The decision was a spinoff of the University of Maryland Strategic Partnership Act, said Laurie Ellen Locasio, vice president for research at the two institutions.

"Now we'll be ranked together by the [National Science Foundation] in the U.S. rankings of research universities and together this makes us [an] over $1 billion public research enterprise," she told the Maryland Life Sciences Advisory Board.

With a multi-billion dollar research powerhouse, the privately-funded Johns Hopkins University, also operating here, Maryland is unusually well-positioned, Locasio said.

"Very few states in the country have the distinction of having two research universities with over a billion dollars in research spending per year. We've really shown up as central to this pandemic."

Martin Rosendale, the CEO of the Maryland Tech Council, said there are so many therapeutics and vaccines in development that keeping up with them all is a daunting task.

Many firms adopted a "drop everything" approach when the scope of the coronavirus challenge started to become apparent, he said.

"We just saw a lot of amazing thing happening here in Maryland so many companies were pivoting immediately to support the response to the pandemic," he said. "They were basically dropping their other work and on their own dime spending their own money evaluating their technologies, their platforms, how they could apply them to COVID-19."

Many of the big players have grabbed global headlines for their work on a possible vaccine. But smaller companies are making potentially valuable strides as well, Commerce Secretary Kelly M. Schulz told the panel.

Other firms are working to develop COVID tests that are faster and more reliable.

The Tech Council formed the Maryland COVID-19 Coalition to bring companies together, "to make sure they knew who each other were and begin a conversation," Rosendale said. Twenty-five firms were part of the coalition's first call; 40 were on the second.

Chris P. Austin, director of the National Center for Advancing Translation Sciences at NIH, told the panel that the federal government has pumped more than $20 billion into COVID research.

"Of that, we know that over $3 billion is coming here to Maryland," Rosendale said. "That's a testament to the amazing vaccine and cell-and-gene therapy industries that have grown up here."

If foundation and other non-government funds are added to the public dollars, "the number is well over $4 billion," he added.

To play off the capital region's strengths in biotech, a group of industry leaders in Maryland, Washington, D.C., and Virginia is organizing a "pandemic and bio-defense center" to help countries around the globe guard against future pandemics.

"Because of the prominence of what's going on with COVID-19 development in our region especially within Maryland with vaccine, diagnostics, and therapeutic research we are sort of the epicenter in the world right now," said Richard A. Bendis, president and CEO of BioHealth Innovation, Inc. in Rockville.

"People are starting to take notice."

Schulz said the Department of Commerce paused its planned marketing efforts in the spring to focus on the pandemic, but now is ready to gear back up again with an "Innovation Uncovered" campaign.

"We're going back to where we wanted to be at the beginning of the year, which was to push the bio- and the life sciences worlds out, because we have heard from [company executives] that Maryland needs to be seen as a strong, tight ecosystem for this industry," she said.

bruce@maryandmatters.org

For more stories from Maryland Matters, visit http://www.marylandmatters.org.

More here:
Maryland Labs Developing Vaccines And Therapeutics, Attracting Federal Dollars - Patch.com

Recommendation and review posted by Bethany Smith

One of many major challenges facing gene therapy a approach to deal with illness by changing a affected persons faulty genes with wholesome ones is that its troublesome to securely ship therapeutic genes to sufferers with out the immune system destroying the gene, and the car carrying it, which might set off life-threatening widespread irritation.

Three a long time in the past researchers thought that gene remedy can be the last word remedy for genetically inherited illnesses like hemophilia, sickle cell anemia, and genetic illnesses of metabolism. However the know-how couldnt dodge the immune response.

Since then, researchers have been searching for methods to good the know-how and management immune responses to the gene or the car. Nevertheless, lots of the methods examined to date have not been completely successful in overcoming this hurdle.

Medicine that suppress the entire immune system, similar to steroids, have been used to dampen the immune response when administering gene remedy. However its troublesome to regulate when and the place steroids work within the physique, they usually create undesirable unwanted side effects. My colleague Mo Ebrahimkhani and I wished to deal with gene remedy with immune-suppressing instruments that have been simpler to regulate.

I am a medical doctor and synthetic biologist involved in gene remedy as a result of six years in the past my father was recognized with pancreatic cancer. Pancreatic most cancers is without doubt one of the deadliest types of most cancers, and the at present out there therapeutics often fail to avoid wasting sufferers. Consequently, novel therapies similar to gene remedy could be the one hope.

[Learn: These tech tendencies outlined 2020 to date, in keeping with 5 founders]

But, many gene therapies fail as a result of sufferers both have already got pre-existing immunity to the car used to introduce the gene or develop one in the midst of remedy. This downside has plagued the sector for many years, stopping the widespread utility of the know-how.

Historically scientists use viruses from which harmful disease-causing genes have been eliminated as automobiles to move new genes to particular organs. These genes then produce a product that may compensate for the defective genes which might be inherited genetically. That is how gene remedy works.

Although there have been examples displaying that gene therapy was helpful in some genetic illnesses, theyre nonetheless not good. Generally, a defective gene is so large that you couldt merely match the wholesome alternative within the viruses generally utilized in gene remedy.

One other downside is that when the immune system sees a virus, it assumes that its a disease-causing pathogen and launches an assault to battle it off by producing antibodies and immune response simply as occurs when individuals catch another infectious viruses, like SARS-CoV-2 or the frequent chilly.

Not too long ago, although, with the rise of a gene-editing technology called CRISPR, scientists can do gene remedy otherwise.

CRISPR can be utilized in some ways. In its main function, it acts as a genetic surgeon with a pointy scalpel, enabling scientists to discover a genetic defect and proper it throughout the native genome in desired cells of the organism. It might probably additionally restore multiple gene at a time.

Scientists can even use CRISPR to show off a gene for a brief time frame after which flip it again on, or vice versa, with out completely altering the letters of DNA that makes up our genome. Which means that researchers like me can leverage CRISPR know-how to revolutionize gene therapies within the coming a long time.

However to make use of CRISPR for both of those features, it nonetheless must be packaged right into a virus to get it into the physique. So some challenges, similar to stopping the immune response to the gene remedy viruses, nonetheless have to be solved for CRISPR-based gene therapies.

Being educated as a synthetic biologist, I teamed up with Ebrahimkhani to make use of CRISPR to check whether or not we may shut down a gene thats liable for the immune response that destroys the gene remedy viruses. Then we investigated whether or not decreasing the exercise of the gene, and dulling the immune response, would permit the gene remedy viruses to be more practical.

[Deep information, every day. Sign up for The Conversations newsletter.]

CRISPR can exactly take away even single items of DNA. KEITH CHAMBERS/SCIENCE PHOTO LIBRARY/Getty Images

A gene called Myd88 is a key gene within the immune system and controls the response to micro organism and viruses, together with the frequent gene remedy viruses. We determined to briefly flip off this gene in the entire physique of lab animals.

We injected animals with a group of the CRISPR molecules that focused the Myd88 gene and seemed to see whether or not this lowered the variety of antibodies that have been produced to particularly battle our gene remedy viruses. We have been excited to see that the animals that obtained our remedy utilizing CRISPR produced much less antibodies towards the virus.

This prompted us to ask what occurs if we give the animal a second dose of the gene remedy virus. Often, the immune response towards a gene remedy virus prevents the remedy from being administered a number of occasions. Thats as a result of after the primary dose, the immune system has seen the virus, and on the second dose, antibodies swiftly assault and destroy the virus earlier than it could possibly ship its cargo.

We noticed that animals receiving multiple dose didnt present a rise in antibodies towards the virus. And, in some instances, the impact of gene remedy improved in contrast with the animals through which we had not paused the Myd88 gene.

We additionally did plenty of different experiments that proved that tweaking the Myd88 gene might be helpful in combating off different sources of irritation. That could possibly be helpful in illnesses like sepsis and even COVID-19.

Whereas we at the moment are starting to enhance this technique by way of controlling the exercise of the Myd88 gene. Our outcomes, now revealed in Nature Cell Biology, present a path ahead to program our immune system throughout gene therapies and different inflammatory responses utilizing the CRISPR know-how.

This text is republished from The Conversation by Samira Kiani, Affiliate Professor of Pathology, University of Pittsburghbeneath a Artistic Commons license. Learn the original article.

See more here:
How CRISPR is tackling the troubling immune response that's plagued gene therapy until now - Best gaming pro

Recommendation and review posted by Bethany Smith

This report focuses on the Global Gene Therapy Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

The latest research report on Gene Therapy market encompasses a detailed compilation of this industry, and a creditable overview of its segmentation. In short, the study incorporates a generic overview of the Gene Therapy market based on its current status and market size, in terms of volume and returns. The study also comprises a summary of important data considering the geographical terrain of the industry as well as the industry players that seem to have achieved a powerful status across the Gene Therapy market.

Get Sample of this Premium Report @ https://industrystatsreport.com/Request/Sample?ResearchPostId=579&RequestType=Sample

Gene Therapy Market Segmentation

Reports include the following segmentation: By Disease Indication Cancer Genetic disorders Cardiovascular diseases Ophthalmology Neurological conditions OthersBy Type of Vectors Viral vectors Non-viral vectorsBy Type of Cells Somatic cells Germline cellsBy Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Gene Therapy Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2020.

The major players in the market Pfizer Inc. Novartis AG Bayer AG Sanofi GlaxoSmithKline plc. Amgen Inc. Boehringer Ingelheim International GmbH uniQure N.V. bluebird bio, Inc. Celgene Corporation Others

Global Gene Therapy MarketThis research report providesCOVID-19 Outbreakstudy accumulated to offer Latest insights about acute features of the Gene Therapy Market. The report contains different market predictions related to marketsize, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary andSWOT analysis.It presents the360-degreeoverview of the competitive landscape of the industries. Gene Therapy Market is showing steadygrowthandCAGRis expected to improve during the forecast period.

The main sources are industry experts from the global Gene Therapy industry, including management organizations, processing organizations, and analytical services providers that address the value chain of industry organizations. We interviewed all major sources to collect and certify qualitative and quantitative information and to determine future prospects. The qualities of this study in the industry experts industry, such as CEO, vice president, marketing director, technology and innovation director, founder and key executives of key core companies and institutions in major biomass waste containers around the world in the extensive primary research conducted for this study We interviewed to acquire and verify both sides and quantitative aspects.

Global Gene Therapy Market: Regional AnalysisThe report offers in-depth assessment of the growth and other aspects of the Gene Therapy market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

Do You Have Any Query Or Specific Requirement @https://industrystatsreport.com/Request/Sample?ResearchPostId=579&RequestType=Methodology

Complete Analysis of the Gene Therapy Market:

Comprehensive assessable analysis of the industry is provided for the period of 2020-2025 to help investors to capitalize on the essential market opportunities.

The key findings and recommendations highlight vital progressive industry trends in the global Gene Therapy market, thereby allowing players to improve effective long term policies

A complete analysis of the factors that drive market evolution is provided in the report.

To analyze opportunities in the market for stakeholders by categorizing the high-growth segments of the market

The numerous opportunities in the Gene Therapy market are also given.

Report Answers Following Questions:

What are the factors driving the growth of the market?

What factors are inhibiting market growth?

What are the future opportunities in the market?

Which are the most dynamic companies and what are their recent developments within the Gene Therapy Market?

What key developments can be expected in the coming years?

What are the key trends observed in the market?

TABLE OF CONTENT

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Read Full Report: https://industrystatsreport.com/Lifesciences-and-Healthcare/Gene-Therapy-Market-Share/Summary

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at sales@brandessenceresearch.com

Blog: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog:https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Blog:https://tcbiznews.com/

Top Trending Reports:

https://brandessenceresearch.com/healthcare/bispecific-antibody-market-size

https://www.marketwatch.com/press-release/cryogenic-pumps-market-size-by-2020-2025-manufacturers-advancements-sales-shares-challenges-opportunities-2020-09-10?tesla=y

https://marketstatsreport.com/anti-ageing-drugs-market-2020-global-demand-key-players-overview-supply-and

https://marketstatsreport.com/clindamycin-phosphate-injection-market-global-industry-analysis-size-share-growth-trends-and

https://marketstatsreport.com/global-clindamycin-phosphate-topical-market-2020-top-manufactures-growth-opportunities-and-investment

Originally posted here:
Gene Therapy Market to Eyewitness Massive Growth by 2026: Leading Key Players Pfizer Inc. Novartis AG Bayer AG Sanofi GlaxoSmithKline plc. Amgen Inc....

Recommendation and review posted by Bethany Smith

[190+ Pages PDF Report] Facts & Factors (FnF) published a market research report onCancer Gene Therapy Market: By Size, Share, Growth, Analysis Covering COVID-19 Impact and Forecast to 2020-2026that includes a research report with TOC including a list of tables and figures in its research offerings.

Cancer Gene Therapy Market Market Report: Industry Insights, 2020-2026

This multi-client research study on theCancer Gene Therapy Market marketprovides in-depth research and analysis into Cancer Gene Therapy Market industry trends, market developments and technological insights. The report provides data and analysis of Cancer Gene Therapy Market penetration across application segments across countries and regions. The report presents a strategic analysis of the Cancer Gene Therapy Markety market through key drivers, challenges, opportunities, and growth contributors.

The global Cancer Gene Therapy Market market delivers value to customers through reliable market size for 2020 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Cancer Gene Therapy Market market size to 2026.

The report presents an introduction to the Cancer Gene Therapy Market market in 2020, analyzing the COVID-19 impact both quantitatively and qualitatively.

Request an Exclusive FREE SAMPLE REPORT of Cancer Gene Therapy Market Market:https://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

(The sample of this report is readily available on request).

The FREE PDF Sample Report Includes:

(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)

Some of Following Top Market Players Profile Included in This Report:

2020 Cancer Gene Therapy Market Market: COVID-19 Impact Analysis

The global rise of COVID-19 has many businesses struggling and confused about what steps to take to minimize the economic impact. A simple look at the stock market will tell you that coronavirus has led to a volatile economy, but there are numerous other factors at play.

The long term COVID-19 impact on the business industry is largely still unknown; hence,Facts and Factors market researchanalysts have already covered the effects of COVID-19 on the business industry at a large level, as well as global and regional levels. Through our coverage below, get a better understanding of the business and economic implications coronavirus has on trends like remote working, consumer shopping behavior, global advertising spend, and essential industries like food, medical, travel, and transportation.

Download the Free Sample Report PDF Brochure Including COVID-19 Business Impact:https://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

Cancer Gene Therapy Market Market 2020: Research Scope & Coverage

The report coversCancer Gene Therapy Market market sizeand growth, characteristics, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography. The market size analysis gives the market size covering both the historic growth of the market, the impact of the COVID 19 virus, and forecasting its recovery. The report also provides a comprehensive analysis of current & future trends and emerging avenues for the growth of this market along with this research also offers an insight into the competitive landscape in terms of new technological developments, untapped segments, and value chain analysis.

The report, Cancer Gene Therapy Market Market, provides up-to-date information about market size, share shifts, and potential risks, as well as in-depth knowledge of products and services, which can help in planning and in executing category management activities. It focuses on the cost-saving aspects of procurement and on providing insights that can lead to the optimization of category spend.

Get Free Customized Copy of Cancer Gene Therapy Market Market Report @https://www.fnfresearch.com/customization/cancer-gene-therapy-market-by-type-ex-vivo-898

(We customize your report according to your research need. Ask our sales team for report customization.)

Competitive Landscape

The market appears to be fragmented and with the presence of several. Thissize of Cancer Gene Therapy Market marketresearch report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies.

Key Takeaways from this Cancer Gene Therapy Market Market Report

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background.

Contact Us (Corporate Office):Facts & FactorsA 2108, Sargam,Nanded City,Sinhagad Road,Pune 411041, IndiaUSA: +1-347-989-3985Email:sales@fnfresearch.comWeb:https://www.fnfresearch.com

Read the original:
Cancer Gene Therapy Market Size Will Expand Post COVID-19 Covered in Forecast Report 2020-2026 - NJ MMA News

Recommendation and review posted by Bethany Smith

Global Coronavirus pandemic has impacted all industries across the globe, Gene Therapy for Ovarian Cancer market being no exception. As Global economy heads towards major recession post 2009 crisis, Cognitive Market Research has published a recent study which meticulously studies impact of this crisis on Global Gene Therapy for Ovarian Cancer market and suggests possible measures to curtail them. This press release is a snapshot of research study and further information can be gathered by accessing complete report. To Contact Research Advisor Mail us @ [emailprotected] or call us on +1-312-376-8303.

The research report on global Gene Therapy for Ovarian Cancer market as well as industry is a detailed study that provides detailed information of major key players, product types & applications/end-users; historical figures, region analysis, market drivers/opportunities & restraints forecast scenarios, strategic planning, and a precise section for the effect of Covid-19 on the market. Our research analysts intensively determine the significant outlook of the global Gene Therapy for Ovarian Cancer market study with regard to primary & secondary data and they have represented it in the form of graphs, pie charts, tables & other pictorial representations for better understanding.

Intravenous, Intratumoral, Intraperitoneal are some of the key types of market. All the type segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2027. Based on the application segment, the global market can be classified into Ovarian Cancer (unspecified), Recurrent Ovarian Epithelial Cancer, Platinum Resistant Ovarian Cancer . The analysis of application segment will help to analyze the demand for market across different end-use industries.

Request Free Sample Copy of Gene Therapy for Ovarian Cancer Market Research [emailprotected] https://cognitivemarketresearch.com/medical-devicesconsumables/gene-therapy-for-ovarian-cancer-market-report#download_report

Amid the COVID-19 pandemic, the industry is witnessing a major change in operations.Some of the key players include Takara Bio, VBL Therapeutics, CELSION, Targovax . key players are changing their recruitment practices to comply with the social distancing norms enforced across several regions to mitigate the risk of infection. Additionally, companies are emphasizing on using advanced recruiting solutions and digital assets to avoid in-person meetings. Advanced technologies and manufacturing process are expected to play a decisive role in influencing the competitiveness of the market players.

Regional Analysis for Gene Therapy for Ovarian Cancer Market:North America (United States, Canada)Europe (Germany, Spain, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, India, Australia, and South Korea)Latin America (Brazil, Mexico, etc.)The Middle East and Africa (GCC and South Africa)

Get A Free Sample of Gene Therapy for Ovarian Cancer Market Report: https://cognitivemarketresearch.com/medical-devicesconsumables/gene-therapy-for-ovarian-cancer-market-report#download_report

NOTE: Whole world is experiencing the impact of Covid-19 pandemic due to its increasing spread hence, the report comprises of an up to date scenario of the Gene Therapy for Ovarian Cancer market report. Research analyst team of our company is understanding & reviewing the Covid19 Impact on Market and all the necessary areas of the market that have been altered due to the change caused by Covid19 impact. Get in touch with us for more precise/in-depth information of the Gene Therapy for Ovarian Cancer market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Gene Therapy for Ovarian Cancer Market Report 2020 (Coronavirus Impact Analysis on Gene Therapy for Ovarian Cancer Market)

At the end of May, many states began lifting lockdown restrictions and reopening in order to revive their economies, despite warnings that it was still too early. As a result, by mid-July, around 33 states were reporting higher rates of new cases compared to the previous week with only three states reporting declining rates. Due to this Covid-19 pandemic, there has been disruptions in the supply chain which have made end-use businesses realize destructive in the manufacturing and business process. During this lockdown period, the plastic packaging helps the products to have longer shelf life as the public would not be able to buy new replacements for the expired products because most of the production units are closed.

About Us:Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

Read this article:
Global and US Gene Therapy for Ovarian Cancer Market to Witness Huge Growth by abc Major Players included in report Takara Bio, VBL Therapeutics,...

Recommendation and review posted by Bethany Smith

TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL's study is being presented at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting.

Data show that VBL's anti-MOSPD2 mAbs significantly inhibited migration of monocytes isolated from all MS patients included in the study (n=33) by up to 97%, regardless of disease severity, gender or active treatment. Notably, the activity was seen not only in the monocytes from relapsing-remitting, but also those from primary progressive and secondary progressive patients with high Expanded Disability Status Scale (EDSS) scores of 5.5-6.5.

We believe our antibodies open up a completely novel mechanism for potential treatment of MS, through blocking the accumulation of monocytes/macrophages in the central nervous system, said Itzhak Mendel, Ph.D., Immunology Director of VBL Therapeutics. This mechanism is differentiated from the existing available treatments, which mostly target T and B cells and therefore, it is not surprising that our antibodies showed activity on top of any patient active therapy. Backed up by strong preclinical results, these first patient-driven proof-of-concept data reinforce the therapeutic potential of our MOSPD2 program.

VBL is currently advancing lead anti-MOSPD2 candidate VB-601 through IND-enabling studies, aiming to start a first-in-human study in 2H 2021.

For a link to VBL's presentation at the MS Virtual 2020 conference, see: LINK

About VBL's VB-600 PlatformVBL is conducting two parallel drug development programs that are exploring the potential of MOSPD2 (motile sperm domain-containing protein 2), a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer. Our VB-600 platform comprises classical anti-MOSPD2 monoclonal antibodies for inflammatory indications, as well as bi-specific antibody candidates for oncology.

About VBLVascular Biogenics Ltd., operating asVBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBLs lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored all comers Phase 1 trial as well as in three VBL-sponsored tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.

Forward Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential, predict, project, should, will, would and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding our programs, including MOSPD2, including their clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, the impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines and clinical results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with theU.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year endedDecember 31, 2019, and subsequent filings with theSEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.VBL Therapeuticsundertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR CONTACT:Michael RiceLifeSci Advisors, LLC(646) 597-6979

The rest is here:
VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS...

Recommendation and review posted by Bethany Smith

LOS ANGELES, United States: QY Research as of late produced a research report titled, Global and United States Precision Cancer Therapies Market Size, Status and Forecast 2020-2026. The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Precision Cancer Therapies market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

The global Precision Cancer Therapies market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Key Companies/Manufacturers operating in the global Precision Cancer Therapies market include: , Abbott Laboratories, Bayer HealthCare, GlaxoSmithKline, OncoGenex Pharmaceuticals, Hospira, Boehringer Ingelheim, AstraZeneca, Aveo Pharmaceuticals

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/2125996/global-and-united-states-precision-cancer-therapies-market

Segmental Analysis

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of global Precision Cancer Therapies market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global Precision Cancer Therapies Market Segment By Type:

Hormone TherapyImmunotherapiesTargeted TherapyMonoclonal Antibody TherapyGene Therapy Precision Cancer Therapies

Global Precision Cancer Therapies Market Segment By Application:

HospitalsDiagnostic CentersOncology ClinicsResearch Institutes

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Precision Cancer Therapies market.

Key questions answered in the report:

For Discount, Customization in the Report Drop Your Query Here: https://www.qyresearch.com/customize-request/form/2125996/global-and-united-states-precision-cancer-therapies-market

TOC

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Precision Cancer Therapies Market Size Growth Rate by Type: 2020 VS 20261.2.2 Hormone Therapy1.2.3 Immunotherapies1.2.4 Targeted Therapy1.2.5 Monoclonal Antibody Therapy1.2.6 Gene Therapy1.3 Market by Application1.3.1 Global Precision Cancer Therapies Market Share by Application: 2020 VS 20261.3.2 Hospitals1.3.3 Diagnostic Centers1.3.4 Oncology Clinics1.3.5 Research Institutes1.4 Study Objectives1.5 Years Considered 2 Global Growth Trends2.1 Global Precision Cancer Therapies Market Perspective (2015-2026)2.2 Global Precision Cancer Therapies Growth Trends by Regions2.2.1 Precision Cancer Therapies Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Precision Cancer Therapies Historic Market Share by Regions (2015-2020)2.2.3 Precision Cancer Therapies Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top Precision Cancer Therapies Players by Market Size3.1.1 Global Top Precision Cancer Therapies Players by Revenue (2015-2020)3.1.2 Global Precision Cancer Therapies Revenue Market Share by Players (2015-2020)3.2 Global Precision Cancer Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by Precision Cancer Therapies Revenue3.4 Global Precision Cancer Therapies Market Concentration Ratio3.4.1 Global Precision Cancer Therapies Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by Precision Cancer Therapies Revenue in 20193.5 Key Players Precision Cancer Therapies Area Served3.6 Key Players Precision Cancer Therapies Product Solution and Service3.7 Date of Enter into Precision Cancer Therapies Market3.8 Mergers & Acquisitions, Expansion Plans 4 Precision Cancer Therapies Breakdown Data by Type (2015-2026)4.1 Global Precision Cancer Therapies Historic Market Size by Type (2015-2020)4.2 Global Precision Cancer Therapies Forecasted Market Size by Type (2021-2026) 5 Precision Cancer Therapies Breakdown Data by Application (2015-2026)5.1 Global Precision Cancer Therapies Historic Market Size by Application (2015-2020)5.2 Global Precision Cancer Therapies Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Precision Cancer Therapies Market Size (2015-2026)6.2 North America Precision Cancer Therapies Market Size by Type (2015-2020)6.3 North America Precision Cancer Therapies Market Size by Application (2015-2020)6.4 North America Precision Cancer Therapies Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe Precision Cancer Therapies Market Size (2015-2026)7.2 Europe Precision Cancer Therapies Market Size by Type (2015-2020)7.3 Europe Precision Cancer Therapies Market Size by Application (2015-2020)7.4 Europe Precision Cancer Therapies Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China Precision Cancer Therapies Market Size (2015-2026)8.2 China Precision Cancer Therapies Market Size by Type (2015-2020)8.3 China Precision Cancer Therapies Market Size by Application (2015-2020)8.4 China Precision Cancer Therapies Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan Precision Cancer Therapies Market Size (2015-2026)9.2 Japan Precision Cancer Therapies Market Size by Type (2015-2020)9.3 Japan Precision Cancer Therapies Market Size by Application (2015-2020)9.4 Japan Precision Cancer Therapies Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 Southeast Asia10.1 Southeast Asia Precision Cancer Therapies Market Size (2015-2026)10.2 Southeast Asia Precision Cancer Therapies Market Size by Type (2015-2020)10.3 Southeast Asia Precision Cancer Therapies Market Size by Application (2015-2020)10.4 Southeast Asia Precision Cancer Therapies Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11 Key Players Profiles11.1 Abbott Laboratories11.1.1 Abbott Laboratories Company Details11.1.2 Abbott Laboratories Business Overview11.1.3 Abbott Laboratories Precision Cancer Therapies Introduction11.1.4 Abbott Laboratories Revenue in Precision Cancer Therapies Business (2015-2020))11.1.5 Abbott Laboratories Recent Development11.2 Bayer HealthCare11.2.1 Bayer HealthCare Company Details11.2.2 Bayer HealthCare Business Overview11.2.3 Bayer HealthCare Precision Cancer Therapies Introduction11.2.4 Bayer HealthCare Revenue in Precision Cancer Therapies Business (2015-2020)11.2.5 Bayer HealthCare Recent Development11.3 GlaxoSmithKline11.3.1 GlaxoSmithKline Company Details11.3.2 GlaxoSmithKline Business Overview11.3.3 GlaxoSmithKline Precision Cancer Therapies Introduction11.3.4 GlaxoSmithKline Revenue in Precision Cancer Therapies Business (2015-2020)11.3.5 GlaxoSmithKline Recent Development11.4 OncoGenex Pharmaceuticals11.4.1 OncoGenex Pharmaceuticals Company Details11.4.2 OncoGenex Pharmaceuticals Business Overview11.4.3 OncoGenex Pharmaceuticals Precision Cancer Therapies Introduction11.4.4 OncoGenex Pharmaceuticals Revenue in Precision Cancer Therapies Business (2015-2020)11.4.5 OncoGenex Pharmaceuticals Recent Development11.5 Hospira11.5.1 Hospira Company Details11.5.2 Hospira Business Overview11.5.3 Hospira Precision Cancer Therapies Introduction11.5.4 Hospira Revenue in Precision Cancer Therapies Business (2015-2020)11.5.5 Hospira Recent Development11.6 Boehringer Ingelheim11.6.1 Boehringer Ingelheim Company Details11.6.2 Boehringer Ingelheim Business Overview11.6.3 Boehringer Ingelheim Precision Cancer Therapies Introduction11.6.4 Boehringer Ingelheim Revenue in Precision Cancer Therapies Business (2015-2020)11.6.5 Boehringer Ingelheim Recent Development11.7 AstraZeneca11.7.1 AstraZeneca Company Details11.7.2 AstraZeneca Business Overview11.7.3 AstraZeneca Precision Cancer Therapies Introduction11.7.4 AstraZeneca Revenue in Precision Cancer Therapies Business (2015-2020)11.7.5 AstraZeneca Recent Development11.8 Aveo Pharmaceuticals11.8.1 Aveo Pharmaceuticals Company Details11.8.2 Aveo Pharmaceuticals Business Overview11.8.3 Aveo Pharmaceuticals Precision Cancer Therapies Introduction11.8.4 Aveo Pharmaceuticals Revenue in Precision Cancer Therapies Business (2015-2020)11.8.5 Aveo Pharmaceuticals Recent Development 12 Analysts Viewpoints/Conclusions 13 Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Original post:
Precision Cancer Therapies Market, Share, Application Analysis, Regional Outlook, Competitive Strategies & Forecast up to 2025 |, Abbott...

Recommendation and review posted by Bethany Smith

Catalents Redwood Bioscience subsidiary is taking the lead role in developing ADCs for Exelixis $EXEL. In one of 2 deals announced this morning, Exelixis is turning to Catalent to do the discovery work on the ADCs, which will employ their SMARTag site-specific bioconjugation platform technology using antibodies out of the biotechs pipeline.

Catalent gets $10 million upfront to trigger the deal, with Exelixis holding worldwide development rights on anything it chooses.

In a separate ADC development deal, Exelixis is turning to NBE-Therapeutics for another pact that could steer more product candidates its way. In this deal Exelixis is paying $25 million upfront to get a 2-year alliance underway.

Exelixis is pursuing both internal drug discovery and external business development approaches to build a pipeline with the potential to make a difference for patients with cancer, saidPeter Lamb, the CSO at Exelixis. John Carroll

Back in the days when investors thought there was still good business to be made in antibiotics, Spero raised a fair bit of capital: a $30 million Series A and B led by Atlas Ventures, a $51.7 million Series C led by GV, and a $77 million IPO. In 2018, they received an up to $54 million contract with BARDA too.

The market for antibiotics has since soured, but that cash has allowed Spero to get through Phase III with its lead drug. And on Tuesday they announced positive results, showing in a 1,372-person study that their oral antibiotic tebipenem was non-inferior to the approved IV antibiotic ertapenem in treating patients with complicated urinary tract infections and acute pyelonephritis.

The drug, said trial investigator Keith Kaye, will give cUTI patients a new oral option after evolving microbiotic resistance had left them with only the IV drug.

Due to the increasing prevalence of antibiotic-resistant bacteria, many patients with cUTI now receive intravenous antibiotics as their only available treatment option, Kaye, who is also director of research in the division of infectious diseases at the University of Michigan Medical School, said in a statement. The much-anticipated data from this head-to-head comparison against an IV standard-of-care carbapenem antibiotic suggest that in many instances oral, outpatient treatment of these complicated bacterial infections is a viable option.

Spero CEO Ankit Mahadevia said it would be the first oral cUTI drug approved in 26 years. The company said it plans to start a rolling NDA and complete it by the second quarter of 2021.

An approval would be a major boon to any biotech, but when it comes to antibiotics, regulatory success doesnt necessarily translate into commercial success. Melinta and Achaoegen are well proof of that. Jason Mast

A UK-based biotech is buying outright a software developer in Brooklyn, NY, in order to bring artificial intelligence to its diagnostics tools.

APIS Assay Technologies announced the acquisition of Beogenomics on Friday, hoping to use data-mining processes to identify biomarker targets in oncology, as well as inflammatory, autoimmune and infectious diseases. The technology from Beogenomics, which has been developing both on-prem and secure cloud-based data analysis solutions, will help support the launch of a new proprietary service line. APIS mainly works in R&D and diagnostics, developing new tests for the prediction, prevention, and diagnosis of disease from discovery to regulatory approval.

The companys business model focuses on three aspects: biomarker diagnostics development, molecular diagnostic contract development, and applied bioinformatics. Max Gelman

Intravacc, a Dutch vaccines company, landed an up to $9.4 million contract from NIAID to develop a vaccine for enterovirus D68, a respiratory virus that can cause paralysis and has become increasingly common in America, Europe and Asia over the last few years.

The small biotech, which also has programs for RSV, gonorrhea and of course Covid-19, will develop an inactivated virus vaccine in Vero cells. The contract is for early product selection through Phase I. Jason Mast

Read this article:
News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero - Endpoints...

Recommendation and review posted by Bethany Smith

Chicago, United States:The global Cell and Gene Therapy Market report offers a complete research study that includes accurate estimations of market growth rate and size for the forecast period 2020-2025. It offers a broad analysis of market competition, regional expansion, and market segmentation by type, application, and geography supported by exact market figures. The all-inclusive market research report also offers Porters Five Forces Analysis and profiles some of the leading players of the global Cell and Gene Therapy Market. It sheds light on changing market dynamics and discusses about different growth drivers, market challenges and restraints, and trends and opportunities in detail. Interested parties are provided with market recommendations and business advice to ensure success in the global Cell and Gene Therapy Market.

Top Key players cited in the report:Amgen Inc., bluebird bio, Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Human Stem Cells Institute, Kite Pharma, Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, .

Get Free PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart): https://www.reporthive.com/request_sample/2369809

The final report will add the analysis of the Impact of Covid-19 in this report Cell and Gene Therapy Market

Cell and Gene Therapy Marketreports offers important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends.

Each segment of the global Cell and Gene Therapy market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Cell and Gene Therapy market through leading segments. The regional study of the global Cell and Gene Therapy market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Cell and Gene Therapy market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global Cell and Gene Therapy Market: Competitive Rivalry

The chapter on company profiles studies the various companies operating in the global Cell and Gene Therapy market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Cell and Gene Therapy market participants in the past few years to remain ahead of the competition.

Global Cell and Gene Therapy Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global Cell and Gene Therapy market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global Cell and Gene Therapy market.

Request For Customization:https://www.reporthive.com/request_customization/2369809

Report Highlights

Table of Contents

Report Overview:It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Cell and Gene Therapy market segments by application, study objectives, and years considered.

Global Growth Trends:There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

Cell and Gene Therapy Market Share by Manufacturer:Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type:It includes analysis of price, production value market share, and production market share by type.

Market Size by Application:This section includes Cell and Gene Therapy market consumption analysis by application.

Profiles of Manufacturers:Here, leading players of the global Cell and Gene Therapy market are studied based on sales area, key products, gross margin, revenue, price, and production.

Cell and Gene Therapy Market Value Chain and Sales Channel Analysis:It includes customer, distributor, Cell and Gene Therapy market value chain, and sales channel analysis.

Market Forecast Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Get Free Sample Copy of this report:https://www.reporthive.com/request_sample/2369809

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

Continue reading here:
COVID-19 Impact on Cell and Gene Therapy Market Research, Size, Growth And Trends 2020 to 2025: Keyplayer-Amgen Inc., bluebird bio, Inc. - Scientect

Recommendation and review posted by Bethany Smith

For the last couple of years, when it came to the vaguely vampiric field of young blood plasma transfusions, there was Alkahest and there was everyone else.

Since the field was briefly mocked onSilicon Valley in 2017, one startup charged $8,000 to $12,000 to pump the elderly with the plasma of young donors and one doctor pitched his clinical trial in a glitzy West Palm Beach gala where he reminded retirees they were likely to die soon, prompting FDAs chief Scott Gottlieb to warn such treatments were unproven and that some patients are being preyed upon by unscrupulous actors. But Alkahest, founded by a Genentech alumn and a Stanford neuroscientist, has promised to take a more measured, scientific approach to the still-fringe science, running phased clinical trials for their plasma-derived products and couching their press releases accordingly.

Now, the plasma giant Grifols is going all-in on their work. On Labor Day, the Spanish company announced they would buy out the remaining shares of the startup they didnt already own, spending $146 million for just over 50% of Alkahests stock.

Grifols is a roughly $15 billion company, so the buyout is not exactly a huge outlay for them. Nor is the nearly $300 million market value this deal places on Alkahest nearly enough to rank them among the industrys most valuable players. Still, the acquisition represents a major validation for a company and a young-blood field that has grown up largely on the fringes of the biomedical mainstream. And it amounts to a step forward for the anti-aging field more broadly, which has struggled to make gains despite significant big-name investment over the last few years.

The new deal is about four times what Grifols paid for the first 45% of Alkahests stock in 2015. The startup has relied on Grifols to collect plasma for its products.

We saw the promise of Alkahests understanding of aging when we made our first investment and entered into a collaboration agreement with them five years ago, Grifols CEO Vctor Grfols said in a statement. Now we see a wealth of plasma-derived and non-plasma therapeutic candidates identified by Alkahest that can significantly support the unmet needs of many diseases associated with aging.

Unlike, say, Ambrosia (the aforementioned $8,000 infusion company), Alkahest doesnt give plasma directly from young donors to the elderly. Instead, it has worked since 2014 on mapping the proteins in plasma and distilling a cocktail of roughly 400 different types of proteins it believes can make a difference in treating Alzheimers and other CNS disorders. Thats a ton of proteins compared to most biologics, which are made of 1, but it amounts to just 3% of whats in plasma. The Long Island Ice Tea of a lead drug is known as GRF-6019. The science is based on work from Stanford neuroscientist Tony Wyss-Coray, which was spun out by former Genentech scientist Karoly Nikolich.

So far, evidence for effectiveness remains scant. Last year, the company said that, in a 47-person Phase II study, patients with mild to moderate Alzheimers maintained their level of cognition for 6 months. But they still have yet to release data from that study and while this is certainly a new approach to the evasive disease, many other therapies have failed after showing promise in early trials. Their Phase I study, published inJAMA, showed little change in cognitive performance tests among 18 Alzheimers patients, although it was only powered for safety.

Alkahest is also testing GRF-6019 in severe Alzheimers patients, an oft-overlooked population, and said recently that it proved safe in a 26-person pilot study. They have studies ongoing in Parkinsons, age-related macular degeneration, and patients with end-stage renal disease and cognitive impairment.

Outside of plasma, the company is also developing an oral drug aimed at another anti-aging target: Eotaxin. Its an immunomodulatory protein, they say, that increases with age. Alkahest is in Phase II studies to see if blocking it can curb Parkinsons and AMD.

See the article here:
Grifols makes a $146M bet on a Stanford play in a controversial anti-aging field - Endpoints News

Recommendation and review posted by Bethany Smith

California lawmakers passed a law that allows consumers to revoke consent for genetic testing companies like 23andMe and Ancestry to use their data, mandating the companies to destroy the DNA samples within 30 days, STAT reported in its weeklynewsletter.

California law boosts genetic data privacy. Business Insider Intelligence

For context, direct-to-consumer (D2C) DNA testing firms often give customers the opportunity to opt into research by consenting to pass along their samples: For instance, 8 million of 23andMe's network of 10 million users haveopted in to participate in research. States are taking the helm at passing D2C genetic testing regulation, while federal lawmakers remain mumcreating a patchworked legal landscape for genetic testing companies to operate in.

Privacy laws have yet to be enacted on a federal level, so state lawmakers are stepping in: Florida recently passedlegislation prohibiting insurance companies from accessing members' genetic insights, which could impact the type and cost of coverage. But as states take charge putting forth their own laws, genetic testing companies will be faced with new obstacles, and it's unclear how they'll navigate adhering to the changing legal ecosystem.

In reference to the new law passed in California, Justin Yedor, a Los Angeles-based data privacy attorney, wascitedin Bloomberg asking, "are [D2C companies] going to provide these rights strictly for Californians or are they going to extend them to all consumers regardless of jurisdiction?" Contending with new rules passed on a state-by-state basis could cause hangups in operations, exacerbating the alreadysofteningD2C genetic testing market.

While a hodgepodge of legislation across the US will be a hurdle, increased privacy laws could assuage consumers' fears and translate into more sales.In a recent YourDNA survey,40%of consumers who had never taken a DNA test cited privacy concerns as the driving reason for why they've shied away. But if companies are transparent about granting consumers more autonomy over their data and how it's handled, they may be more likely to take the plunge.

Still, we think high-flying genetic testing firms will lean more heavily on their healthcare-focused initiatives as they navigate the shifting D2C realm: Some DNA testing firms likeColorandYouScriptthe latter of which is now owned by Invitaeare powering hospitals' precision medicine initiatives, for example.

Want to read more stories like this one? Here's how you can gain access:

Are you a current Insider Intelligence client? Log in here.

See the rest here:
New California law gives consumers more agency over data they share with genetic testing firms - Business Insider

Recommendation and review posted by Bethany Smith

23andme has long been known as a consumer genetic testing unicorn. But CEO Anne Wojcicki describes it differently, as the peoples research company.

The California-based unicorn is now focused on a partnership with pharma giant GlaxoSmithKline to discover new drugs using data culled from millions of 23andMe customers, and Wojcicki said Wednesday at the STAT Health Tech Summit that she hoped the companys customers would feel proud if a drug developed with their data reaches the market.

Wojcicki, answering a question from moderator Matthew Herper of STAT, didnt outline any specific steps that the company would take to ensure that its customers could benefit from medications developed with their data. Nor did she detail how 23andMe would work with GSK on access issues.

advertisement

Any such decisions are years away, a 23andMe spokesperson later noted, which should give the company time to figure out a way to ensure its customers benefit. The first medicine being developed by the partners, an anti-cancer antibody, is only now starting clinical trials.

If you look at our mission, its about people having access to, understanding, and benefiting from the human genome, Wojcicki said. I think that they can do that with information as well with medications.

advertisement

I think theres a lot to do with the marketing and messaging and actually how [a drug] is sold that we will be able to address when were lucky enough to actually have that kind of program, she said.

The experimental cancer drug that entered clinical trials in July was actually one of the early programs under Richard Scheller, Wojcicki noted. Scheller, 23andMes former chief scientific officer who was considered an instrumental figure in the companys push into drug development, left in July 2019.

In 2018, the company signed an exclusive four-year deal with GSK, with the option to extend their work an extra year. The companies are working on about 30 drug programs together.

At the time the deal was announced, 23andMe faced some backlash for providing information distilled from its consumer clients to pharmaceutical companies. Both companies have argued that they are transparent about how consumers data is used; the press release announcing the deal noted that 23andMe customers would have to opt-in before their de-identified data was shared with GSK.

I think what you see is that for people who are really sick, they want to make a difference. They want to make a difference in their life or they want to make a difference in the lives of their children, Wojcicki said on Wednesday. People participate all the time in studies at Stanford or with Pfizer or with other groups. People want to see their information used for good.

As part of the collaboration, GSK invested $300 million in the genetic testing company; the companies agreed to evenly split the cost of the work done as part of the collaboration, which GSK hoped would improve the probability of R&D success, according to its 2018 annual report.

That focus on genetically validated targets can double the probability of success, said GSKs chief scientific officer Hal Barron, who joined Wojcicki on the summit panel. For the same investment, we could get twice as many molecules out.

GSKs $300 million investment was enough to buy 14.5% of 23andMe, which is still privately held; Wojcicki noted Wednesday that after 14 years, it is not a profitable company.

23andMes core business is selling genetic testing packages to people who are interested in learning more about their ancestry, their predisposition to certain genetic diseases, or their ability to metabolize certain drugs.

In 2017, the company received clearance from the Food and Drug Administration to market its tests as a way to detect a select group of hereditary conditions: Parkinsons disease, a type of Gaucher disease, several hereditary blood disorders, and alpha-1 antitrypsin deficiency. Another FDA clearance followed in 2018 for pharmacogenetic tests, which look for genetic markers of drug metabolism.

Wojcicki said the company would be rolling out a number of [pharmacogenetics] reports to our customers in the near future.

Read more here:
23andMe's aim: Getting customers drugs developed with their data - STAT

Recommendation and review posted by Bethany Smith

[190+ Pages PDF Report] Facts & Factors (FnF) published a market research report onResearch Report on Direct to Consumer Genetic Testing Market: By Product Type, Size, Share, Applications, Growth, Analysis and Forecast, 2020-2026that includes a research report with TOC including a list of tables and figures in its research offerings.

Direct to Consumer Genetic Testing Market Report: Industry Insights, 2020-2026

This multi-client research study on theDirect to Consumer Genetic Testing marketprovides in-depth research and analysis into Direct to Consumer Genetic Testing industry trends, market developments and technological insights. The report provides data and analysis of Direct to Consumer Genetic Testing penetration across application segments across countries and regions. The report presents a strategic analysis of the Direct to Consumer Genetic Testingy market through key drivers, challenges, opportunities, and growth contributors.

The global Direct to Consumer Genetic Testing market delivers value to customers through reliable market size for 2020 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Direct to Consumer Genetic Testing market size to 2026.

The report presents an introduction to the Direct to Consumer Genetic Testing market in 2020, analyzing the COVID-19 impact both quantitatively and qualitatively.

Request an Exclusive FREE SAMPLE REPORT of Direct to Consumer Genetic Testing Market:https://www.fnfresearch.com/sample/direct-to-consumer-genetic-testing-market-by-test-718

(The sample of this report is readily available on request).

The FREE PDF Sample Report Includes:

(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)

Some of Following Top Market Players Profile Included in This Report:

2020 Direct to Consumer Genetic Testing Market: COVID-19 Impact Analysis

The global rise of COVID-19 has many businesses struggling and confused about what steps to take to minimize the economic impact. A simple look at the stock market will tell you that coronavirus has led to a volatile economy, but there are numerous other factors at play.

The long term COVID-19 impact on the business industry is largely still unknown; hence,Facts and Factors market researchanalysts have already covered the effects of COVID-19 on the business industry at a large level, as well as global and regional levels. Through our coverage below, get a better understanding of the business and economic implications coronavirus has on trends like remote working, consumer shopping behavior, global advertising spend, and essential industries like food, medical, travel, and transportation.

Download the Free Sample Report PDF Brochure Including COVID-19 Business Impact:https://www.fnfresearch.com/sample/direct-to-consumer-genetic-testing-market-by-test-718

Direct to Consumer Genetic Testing Market 2020: Research Scope & Coverage

The report coversDirect to Consumer Genetic Testing market sizeand growth, characteristics, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography. The market size analysis gives the market size covering both the historic growth of the market, the impact of the COVID 19 virus, and forecasting its recovery. The report also provides a comprehensive analysis of current & future trends and emerging avenues for the growth of this market along with this research also offers an insight into the competitive landscape in terms of new technological developments, untapped segments, and value chain analysis.

The report, Direct to Consumer Genetic Testing Market, provides up-to-date information about market size, share shifts, and potential risks, as well as in-depth knowledge of products and services, which can help in planning and in executing category management activities. It focuses on the cost-saving aspects of procurement and on providing insights that can lead to the optimization of category spend.

Get Free Customized Copy of Direct to Consumer Genetic Testing Market Report @https://www.fnfresearch.com/customization/direct-to-consumer-genetic-testing-market-by-test-718

(We customize your report according to your research need. Ask our sales team for report customization.)

Competitive Landscape

The market appears to be fragmented and with the presence of several. Thissize of Direct to Consumer Genetic Testing marketresearch report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies.

Key Takeaways from this Direct to Consumer Genetic Testing Market Report

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background.

Contact Us (Corporate Office):Facts & FactorsA 2108, Sargam,Nanded City,Sinhagad Road,Pune 411041, IndiaUSA: +1-347-989-3985Email:sales@fnfresearch.comWeb:https://www.fnfresearch.com

Read the original here:
Direct to Consumer Genetic Testing Market Size & Share Unfolding the Growth During Forecast Year 2020-2026 - Kewaskum Statesman News Journal

Recommendation and review posted by Bethany Smith